Valuation: Tengion, Inc.

Market Cap 1L 95.13T 89.18T 81.32T 2L 1.05Cr 2L 10.5L 4L 52.43L 4L 4L 1.75Cr P/E 2012
-0.14x
P/E 2013 -0.05x
Enterprise Value 55.52L 48.12L 45.11L 41.13L 77.4L 53Cr 78.64L 5.31Cr 2.07Cr 27Cr 2.08Cr 2.04Cr 88Cr EV / Sales 2012
-
EV / Sales 2013 -
Free-Float
100%
Yield 2012 *
-
Yield 2013 -
Change 5-day change 1-year change 3-year change Capi.($)
-2.78%+16.67% - - 402
-1.87%+0.48%-42.23%-43.78% 62Cr
-2.46%-6.52%+127.40% - 42Cr
+0.71%+12.01%-32.53%-12.73% 14Cr
+1.83%-9.02%-12.25%+40.51% 8.54Cr
Average -0.91%+2.75%+10.10%-5.33% 31.72Cr
Weighted average by Cap. -1.54%+4.60%+17.44%-30.27%

Financials

2012 2013
Net sales - -
Net income -1.69Cr -1.47Cr -1.38Cr -1.25Cr -2.36Cr -161.57Cr -2.4Cr -16Cr -6.32Cr -81Cr -6.36Cr -6.22Cr -269.8Cr -1.89Cr -1.64Cr -1.54Cr -1.4Cr -2.64Cr -180.64Cr -2.68Cr -18Cr -7.07Cr -90Cr -7.11Cr -6.95Cr -301.64Cr
Net Debt 37.33L 32.36L 30.33L 27.66L 52.04L 36Cr 52.87L 3.57Cr 1.39Cr 18Cr 1.4Cr 1.37Cr 59Cr 54.42L 47.17L 44.22L 40.32L 75.87L 52Cr 77.08L 5.21Cr 2.03Cr 26Cr 2.04Cr 2Cr 87Cr
Logo Tengion, Inc.
Tengion, Inc. is a regenerative medicine company focused on discovering, developing, manufacturing and commercializing a range of neo-organs, or products composed of living cells, with or without synthetic or natural materials, implanted or injected into the body to engraft into, regenerate, or replace a damaged tissue or organ.  The Company, by using its Organ Regeneration Platform, it creates neo-organs using patient’s own cells.  The Company, based on its clinical and preclinical experience is leveraging its Organ Regeneration Platform to develop Neo-Kidney Augment for patients with advanced chronic kidney disease and Neo-Urinary Conduit for bladder cancer patients who are in need of a urinary diversion. The Company’s product candidates are intended to delay or eliminate the need for chronic disease therapies, organ transplantation, and the administration of anti-rejection medications.
Employees
-